Clinical bottom line
Artificial intelligence (AI) applications in tumor angiogenesis profiling represent an emerging frontier in pathology, offering potential to enhance the prediction of pathological features such as tumor aggressiveness, vascular density, and treatment response. Current evidence suggests AI models integrating gene expression and microenvironmental data related to angiogenesis can identify complex patterns beyond conventional histopathology. However, these approaches remain largely investigational, with limited validation in routine clinical workflows. Pathologists should view AI-assisted angiogenesis profiling as a promising hypothesis-generating tool that may augment, but not replace, established diagnostic criteria pending further validation.
What the evidence shows
Tumor angiogenesis is a critical hallmark of cancer progression, driven by complex interactions between tumor cells, endothelial cells, and the microenvironment (Folkman et al., 2007). Gene expression profiling studies have identified angiogenesis-related signatures that correlate with tumor phenotype and prognosis (van Beijnum et al., 2006). AI algorithms leveraging such multi-omic data can detect subtle angiogenic patterns, including non-coding RNA regulation and myeloid cell contributions, that traditional pathology may miss (Laham-Karam et al., 2023; Ferrara et al., 2010).
For example, non-coding RNAs have emerged as key modulators of physiological and pathological angiogenesis, influencing endothelial cell behavior and vessel formation (Laham-Karam et al., 2023). AI models trained on transcriptomic datasets can integrate these signals to predict angiogenic activity and potential tumor aggressiveness. Similarly, myeloid cells contribute to vascular endothelial growth factor (VEGF)-independent angiogenesis, a mechanism implicated in resistance to anti-angiogenic therapies (Ferrara et al., 2010). AI approaches incorporating immune cell profiling may thus improve prediction of tumor vascularization patterns and therapeutic response.
The tumor microenvironment, including extracellular matrix components and stromal cells, also modulates angiogenesis (Ribatti et al., 2016). AI-based spatial analysis of these features in histopathological images can enhance detection of angiogenic hotspots and vascular heterogeneity. Furthermore, key molecular players such as neuropilins and plexin receptors have been implicated in tumor angiogenesis and progression, representing candidate biomarkers for AI-driven predictive models (Neufeld et al., 2007).
Despite these advances, most studies remain preclinical or retrospective, with limited prospective validation in diverse tumor types. The integration of AI with angiogenesis profiling is still evolving, requiring standardized datasets and rigorous benchmarking against established pathological assessments.
Caveats and uncertainty
Several limitations temper enthusiasm for immediate clinical adoption. First, many AI models rely on high-dimensional gene expression or multi-omic data not routinely available in standard pathology labs, limiting generalizability. Second, heterogeneity in tumor angiogenesis across cancer types and stages complicates model training and validation. Third, the biological complexity of angiogenesis, involving redundant and compensatory pathways, challenges the specificity of AI predictions.
Moreover, the interpretability of AI models remains a concern; black-box algorithms may identify correlations without clear mechanistic insight, raising questions about clinical trustworthiness. The impact of pre-analytical variables, such as tissue fixation and sampling bias, on AI angiogenesis profiling is not fully understood. Finally, prospective clinical trials demonstrating improved diagnostic accuracy or patient outcomes with AI-assisted angiogenesis assessment are lacking.
How this may change practice
If validated, AI-driven tumor angiogenesis profiling could complement traditional pathology by providing quantitative, reproducible assessments of vascular features linked to prognosis and treatment response. This could guide personalized therapy decisions, particularly in cancers where anti-angiogenic agents are used. AI tools may also facilitate earlier detection of aggressive angiogenic phenotypes, prompting timely intervention.
Pathologists may increasingly integrate AI outputs with morphological and immunohistochemical findings to refine tumor classification and risk stratification. Additionally, AI models could identify novel angiogenesis-related biomarkers for targeted therapy development. However, widespread clinical implementation will require standardized protocols, regulatory approval, and education to ensure appropriate interpretation and use.